The Pharmaceuticals and Medical Devices Agency (PMDA) of Japan has announced that it is accepting public comments on its draft regulatory science standards.
Commenters are instructed to send their feedback via email, replacing the placeholder “[at]” with “@” in the provided address. The agency notes that any information submitted may be made public, except personal identifiers such as name, organization, address, telephone, fax, email, and attached supporting data.
The PMDA states that while all comments will be considered in preparing the final Japanese drafts, it will not provide individual responses. It also warns that the website content may contain machine‑translation errors and that attached files (PDF, Excel, Word, PowerPoint) are not translated.
Regulatory UpdatesSep 8, 2026•1 min read
PMDA Invites Public Comments on Draft Regulatory Science Standards
The PMDA outlines how to submit comments on draft regulatory science standards, noting email formatting, public disclosure of submissions, and no individual replies.
Compiled by the PharmaCountry team · Source: PMDA Japan
Ratings
(0)
(0)
(0)
(0)
(0)
More articles
View all insightsResearch & Reports
Global Finished Dosage Manufacturing Landscape 2026
Oct 5, 2026
Regulatory UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
Sep 28, 2026
AnalysisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
Sep 28, 2026
Leave your rating